Physician profile
Ajay Kumar
NPI 1871545111
$12,105.78
in general payments reported to CMS, 2019-2025
29 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 80% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $1,934 · 2021: $1,759 · 2022: $1,697 · 2023: $2,044 · 2024: $1,127 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Travel and Lodging: $1,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.15 |
| Travel and Lodging | $1,826.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,443.17 | 2019-2023 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,975.02 | 2019-2025 | Infinion 16, General - Pain Management |
| Pacira Pharmaceuticals Incorporated | $1,684.80 | 2024-2025 | Iovera |
| Medtronic, INC. | $1,269.26 | 2021-2025 | Venaseal, Intellis Adaptivestim, Medtronic Reusable Instruments |
| Medtronic USA, INC. | $822.20 | 2019 | |
| Nevro Corp. | $555.08 | 2020-2024 | Senza |
| Nalu Medical, INC. | $347.21 | 2022-2024 | Nalu Neurostimulation System |
| Globus Medical, INC. | $179.06 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $125.71 | 2019-2023 | Belbuca |
| Relievant Medsystems, INC. | $84.64 | 2019 | |
| Spr Therapeutics, INC | $84.13 | 2024-2025 | Sprint Pns System |
| Depuy Synthes Sales INC. | $71.87 | 2019-2023 | Orthovisc |
| Bioventus LLC | $68.15 | 2022-2024 | Stimrouter Implantable Kit |
| Nuvasive, INC. | $42.43 | 2023 | Xlif |
| Virtus Pharmaceuticals LLC | $41.45 | 2025 | Levorphanol Tartrate |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.22 | 2019-2021 | |
| Saluda Medical Americas, INC. | $33.19 | 2024 | Evoke |
| Arbor Pharmaceuticals, INC. | $29.47 | 2020-2021 | |
| Avanos Medical | $28.87 | 2022 | |
| Biotronik Nro, INC. | $27.64 | 2025 | Prospera |
| Grt US Holding, INC. | $26.83 | 2021 | |
| Fidia Pharma USA INC. | $20.02 | 2019 | |
| Orthogenrx INC. | $17.27 | 2019 | |
| Painteq LLC | $17.05 | 2021 | |
| Horizon Therapeutics Plc | $16.91 | 2021 | |
| Glaxosmithkline, LLC. | $15.35 | 2025 | Nucala |
| Stratus Medical, LLC | $14.80 | 2022 | |
| Lilly USA, LLC | $14.64 | 2020 | |
| Amgen INC. | $14.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.